Clinical Neuroscience Solutions, Inc

Summary

Clinical Neuroscience Solutions, Inc is a medical facility located in Jacksonville, Florida. This center is recognized for care of Depression, Major Depressive Disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder (ADHD), Migraine and other specialties. Clinical Neuroscience Solutions, Inc is involved with conducting 186 clinical trials across 91 conditions. There are 4 research doctors associated with this hospital, such as Nandita Jones, Nandita Joshi Jones, John Joyce, and John Mark Joyce.

Top PIs

Clinical Trials running at Clinical Neuroscience Solutions, Inc

Depression

Migraine

Major Depressive Disorder

Bipolar Disorder

Vestibular Migraine

Diabetic Neuropathy

Headache

COVID-19

Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

Seltorexant

for Depression

This trial is testing seltorexant to see if it can help people with depression and insomnia who haven't improved with their current antidepressants. Seltorexant aims to improve mood and sleep by acting on certain brain receptors.

Recruiting

1 award

Phase 3

21 criteria

Icalcaprant

for Depression

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE). Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with major depressive disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to placebo treatment. Around 195 adult participant with major depressive disorder will be enrolled in approximately 35 sites in North America. Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 30-day safety follow-up. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Recruiting

1 award

Phase 2

1 criteria

Zelquistinel

for Depression

The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

Recruiting

0 awards

Phase 2

5 criteria